Table 1
| Â | Truvada | Kivexa | p-value |
|---|---|---|---|
Total number | 129 | 103 | Â |
Male | 119 (92.3%) | 96 (93.2%) | 0.78 |
Female | 10 | 7 | Â |
Age (median, IQR) | 38 (32.43) | 38 (32.43) | Â |
Ethnicity | Â | Â | Â |
African | 28 (21.7%) | 39 (37.9%) | 0.001 |
Causcasian | 95 (73.6%) | 55 (50.5%) | 0.001 |
Other | 6 (4.7%) | 12 (11.6%) | 0.001 |
Smoker | 51 (42.5%) | 31 (30.4%) | 0.06 |
History of cardiovascular event | 5 (3.9%) | 4 (3.9%) | 0.63 |
Hypertensive | 9 (7.0%) | 13 (12.6%) | 0.14 |
Diabetic | 3 (2.3%) | 6 (5.8%) | 0.14 |
HBV co-infected | 13 (10.1%) | 1 (1.0%) | 0.02 |
HCV co-infected | 1 (0.8%) | 4 (3.9%) | 0.27 |
AIDS diagnosis | 26 (20.2%) | 19 (18.5%) | 0.74 |
ART experienced | 63 (48.8%) | 53 (51.5%) | 0.74 |
Current drug | Â | Â | Â |
PI | 32 (24.8%) | 19 (18.5%) | 0.25 |
NNRTI | 97 (75.2%) | 84 (81.6%) | Â |
Baseline laboratory markers | Â | Â | Â |
CD4 (cells/mm3) median | 235 | 228 | 0.49 |
Viral load (log copies/ml) median | 4.5 | 3.8 | 0.07 |
Cholesterol (mmol/l) median | 4.3 | 4.5 | 0.05 |
HDL (mmol/l) median | 1.1 | 1.2 | 0.52 |
Triglyceride (mmol/l) median | 1.4 | 1.3 | 0.59 |
GFR | 110 | 107 | 0.14 |